Cambridge, MA
Vigil Neuroscience is the world’s first microglia-focused therapeutics company. Our purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain’s immune system. We are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families.
vigilneuro.comThese are collections Vigil Neuroscience is a part of. Click on the collection name to view similar companies.
Post Ipo Equity
$40,000,000
IPO
Unknown
Series B
$90,000,000
Series A
$50,000,000
0 out of 5 stars
Based on 0 reviews
Worked here? Share your experience. Help others decide if this company is right for them. Write a review on Vigil Neuroscience.